| Identification | More | [Name]
Fentanyl citrate | [CAS]
990-73-8 | [Synonyms]
FENTANYL CITRATE
FENTANYL CITRATE SALT
FENTANYL DIHYDROGEN CITRATE
N-PHENYL-N-[1-(2-PHENYLETHYL)-4-PIPERIDINYL]PROPANAMIDE CITRATE SALT
fentaz
mcn-jr4263
mcn-jr-4263-49
n-(1-phenethyl-4-piperidinyl)propionanilidedihydrogencitrate
n-(1-phenethyl-4-piperidyl)-propionanilidcitrate(1:1)
n-(1-phenethyl-4-piperidyl)propionanilidecitrate
n-(1-phenethyl-4-piperidyl)propionanilidedihydrogencitrate
phentanylcitrate
r5240
sublimaze
FENTANYL CITRATE 100 UG PER ML*IN MEOH-T-BUOH METHA
FENTANYL CITRATE--DEA SCHEDULE II
FentanylCitrate[Dd]
Leptanal citrate
N-(Phenyl)-N-(1-[2-phenylethyl]-4-piperidinyl)propanamide Citrate
Propanamide, N-phenyl-N-1-(2-phenylethyl)-4-piperidinyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) | [EINECS(EC#)]
213-588-0 | [Molecular Formula]
C28H36N2O8 | [MDL Number]
MFCD00058359 | [Molecular Weight]
528.59 | [MOL File]
990-73-8.mol |
| Chemical Properties | Back Directory | [Appearance]
White Powder | [Melting point ]
153-156°C | [Fp ]
11 °C | [storage temp. ]
2-8°C
| [solubility ]
Soluble in water, freely soluble in methanol, sparingly soluble in ethanol (96 per cent). | [form ]
Powder | [color ]
Crystals | [Water Solubility ]
Soluble to 40 mM in water | [Usage]
Used as an analgesic. Controlled substanc | [CAS DataBase Reference]
990-73-8(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
T+,T,F | [Risk Statements ]
R26/27/28:Very Toxic by inhalation, in contact with skin and if swallowed .
R42/43:May cause sensitization by inhalation and skin contact .
R39/23/24/25:Toxic: danger of very serious irreversible effects through inhalation, in contact with skin and if swallowed .
R23/24/25:Toxic by inhalation, in contact with skin and if swallowed .
R11:Highly Flammable. | [Safety Statements ]
S7:Keep container tightly closed .
S16:Keep away from sources of ignition-No smoking .
S36/37:Wear suitable protective clothing and gloves .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) .
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection . | [RIDADR ]
UN 2811 6.1/PG 2
| [WGK Germany ]
3
| [RTECS ]
UE5600000
| [HazardClass ]
6.1(b) | [PackingGroup ]
III | [HS Code ]
2933330000 | [Safety Profile]
Poison by ingestion, subcutaneous, and intravenous routes. When heated to decomposition it emits toxic fumes of NOx. See also PHENTANYL. | [Toxicity]
LD50 in mice (mg/kg): 11.2 i.v.; 62 s.c. (Gardocki, Yelnosky) |
| Hazard Information | Back Directory | [Chemical Properties]
White Powder | [Uses]
Fentanyl citrate can be used as an analgesic.
| [Definition]
ChEBI: The citric acid salt of fentanyl, comprising equimolar amounts of citric acid and fentanyl. A mu-opioid receptor agonist, it is a potent opioid analgesic used in the management of labour pain, postoperative pain, and chronic intractable canc
r pain. It is also widely used as the analgesic component of balanced anaesthesia. | [Brand name]
Actiq (Cephalon); Sublimaze (Akorn). | [Biological Activity]
Potent and selective μ -opioid receptor agonist (K i values are 7.0, 151 and 470 nM for μ -, δ - and κ -opioid receptors respectively). Displays antinociceptive activity in vivo . | [Clinical Use]
A fentanyl patch is available for the treatment of severe chronic pain. This dosage form delivers
fentanyl transdermally and provides effective analgesia for periods of up to 72 hours. In 1999,
fentanyl also became available in a lollipop dose form for absorption from the oral cavity.
Fentanyl's short duration of action after parenteral dose is caused by redistribution rather than by
metabolism or excretion. Repeated doses of fentanyl can result in accumulation and toxicities.
Elderly patients usually are more sensitive to fentanyl and require lower doses.
Opioids have a wide spectrum of P-glycoprotein (P-gp) activity, acting as both substrates and
inhibitors, which might contribute to their varying CNS-related effects. Although fentanyl,
sufentanil, and alfentanil did not behave as P-gp substrates, they inhibited the in vitro
P-gp–mediated efflux of drugs known to be P-gp transported, such as digoxin, increasing their
blood levels and the potential for important drug interactions by inhibition of P-gp efflux
transporter. |
|